Rocket Pharmaceuticals Stock News

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 163.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rar

A Rocket Pharmaceuticals, Inc. regulatory filing to the FDA of LV RP-L201 for Leukocyte Adhesion Deficiency-I is expected in the 1st half of 2023. A regulatory filing to the FDA of LV RP-L102 for Fanc

Shares of gene therapy concern Rocket Pharmaceuticals have fallen 75% from their all-time high set in February 2021 with the only setback a three-month hold on one clinical trial. Although the company

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 211.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen

Shares have lost 15% year to date. Company wisely adopted a platform-agnostic approach to address first-in-class opportunities across the gene therapy pipeline.

Raymond James has decided to maintain its Outperform rating of Rocket Pharmaceuticals (NASDAQ:RCKT) and raise its price target from $22.00 to $24.00. Shares of Rocket Pharmaceuticals are trading up 2.

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy prog

Upgrades According to Wedbush, the prior rating for Diebold Nixdorf Inc (NYSE:DBD) was changed from Neutral to Outperform. Diebold Nixdorf earned $1.61 in the first quarter, compared to $0.29 in the

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies

Rocket is running a number of successful rare disease programs. Their data so far is excellent.

Over the past 3 months, 4 analysts have published their opinion on Rocket Pharmaceuticals (NASDAQ:RCKT) stock. These analysts are typically employed by large Wall Street banks and tasked with understa

During the last session, Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)’s traded shares were 0.47 million, with the beta value of the company hitting 1.81. At the end of the trading day, the stock’s price was $15.69, reflecting an intraday loss of -5.77% or -$0.96. The 52-week high for the RCKT share is $58.72, that puts it down … Is Rocket Pharmaceuticals Inc.’s (NASDAQ: RCKT) 6.73% Gain This Week Telling Us Something New? Read More »

Rocket Pharmaceuticals press release (RCKT): Q4 GAAP EPS of -$0.69 beats by $0.04.Cash, cash equivalents and investments as of December 31, 2021, were $388.7 million.